Outcomes in patients with pancreatic cancer as a secondary malignancy: a retrospective single-institution study
- 8 Downloads
This study aimed to evaluate the clinicopathological features and oncological outcomes of pancreatic cancer (PC) patients with prior malignancies (2nd primary PC) compared with those of patients without any prior malignancies in their history (1st primary PC).
We retrospectively reviewed clinical data from 185 PC patients undergoing surgical resection. Patients were divided into the 1st and 2nd primary PC groups.
Forty-three patients (23.2%) had a history of prior malignancy. The 2nd primary PC group was significantly older than the 1st primary PC group (mean, 72.1 vs. 65.9 years, respectively, P < 0.001) and was more frequently asymptomatic compared to the 1st primary PC group (67.4 vs. 31.0%, respectively, P < 0.001). The tumor size was larger, and extrapancreatic nerve plexus invasion, venous invasion, and lymph node metastasis were more frequently observed in the 1st primary PC group. The rate of adjuvant therapy administration was lower in 2nd primary PC patients (72.5 vs. 51.2%, P = 0.009). In the survival analysis, no significant difference in overall or disease-free survival was found between the two groups (16.8 vs. 16.4 months, P = 0.725, and 8.7 vs. 9.3 months, P = 0.284, respectively).
Despite significant surveillance bias, such as earlier detection in 2nd primary PC, the outcomes of patients with 2nd primary PC were comparable to those of patients with 1st primary PC. Further investigation with a larger sample size and matching for patient age and tumor stage in both groups is needed to elucidate the biological features of 2nd primary PC.
KeywordsMultiple primary malignancy Pancreatic cancer Second primary cancer Systemic inflammatory response
Hoshimoto S designed the report; Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, and Ogata Y were in charge of patient treatment and data acquisition; Hoshimoto S analyzed the data and drafted the manuscript; Hishinuma S and Ogata Y critically revised the manuscript. All authors approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 4.Shen M, Boffetta P, Olsen JH, Andersen A, Hemminki K, Pukkala E, Tracey E, Brewster DH, McBride M, Pompe-Kirn V, Kliewer EV, Tonita JM, Chia KS, Martos C, Jonasson JG, Colin D, Scélo G, Brennan P (2006) A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 163:502–511. https://doi.org/10.1093/aje/kwj073 CrossRefPubMedGoogle Scholar
- 5.Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH (2006) Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98:15–25. https://doi.org/10.1093/jnci/djj001 CrossRefPubMedGoogle Scholar
- 6.Kato H, Usui M, Isaji S, Nagakawa T, Wada K, Unno M, Nakao A, Miyakawa S, Ohta T (2013) Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese society of pancreatic surgery. J Hepatobiliary Pancreat Sci 20:601–610. https://doi.org/10.1007/s00534-013-0595-1 CrossRefPubMedGoogle Scholar
- 7.Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW, European Study Group for Pancreatic Cancer (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6 CrossRefGoogle Scholar
- 8.Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y, JASPAC 01 Study Group (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257. https://doi.org/10.1016/S0140-6736(16)30583-9 CrossRefGoogle Scholar
- 9.Ahmad J, Grimes N, Farid S, Morris-Stiff G (2014) Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 13:474–481. https://doi.org/10.1016/S1499-3872(14)60284-8 CrossRefPubMedGoogle Scholar
- 10.Aurello P, Tierno SM, Berardi G, Tomassini F, Magistri P, D’Angelo F, Ramacciato G (2014) Value of preoperative inflammation-based prognostic scores in predicting overall survival and disease-free survival in patients with gastric cancer. Ann Surg Oncol 21:1998–2004. https://doi.org/10.1245/s10434-014-3533-9 CrossRefPubMedGoogle Scholar
- 13.Aziz MH, Sideras K, Aziz NA et al (2018) The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg 270:139–146. https://doi.org/10.1097/SLA.0000000000002660 CrossRefGoogle Scholar
- 14.Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y (2016) Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore) 95:e3582. https://doi.org/10.1097/MD.0000000000003582 CrossRefGoogle Scholar
- 16.Hackert T, Tjaden C, Muller S, Hinz U, Hartwig W, Strobel O, Fritz S, Schmied B, Buchler MW, Werner J (2012) Extrapancreatic malignancies in patients with pancreatic cancer: epidemiology and clinical consequences. Pancreas 41:212–217. https://doi.org/10.1097/MPA.0b013e3182240602 CrossRefPubMedGoogle Scholar
- 18.Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030. https://doi.org/10.1038/sj.bjc.6601242 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Bosman FT, International Agency for Research on Cancer, World Health Organization (2010) WHO classification of tumours of the digestive system. International Agency for Research on Cancer. Lyon, FranceGoogle Scholar
- 20.Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefGoogle Scholar
- 21.Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, Conlon K, del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-del Castillo C, Fingerhut A, Friess H, Gouma DJ, Hackert T, Izbicki J, Lillemoe KD, Neoptolemos JP, Olah A, Schulick R, Shrikhande SV, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M, International Study Group on Pancreatic Surgery (ISGPS) (2017) The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161:584–591CrossRefGoogle Scholar
- 23.Neugut AI, Ahsan H, Robinson E (1995) Pancreas cancer as a second primary malignancy: a population-based study. Cancer 76:589–592. https://doi.org/10.1002/1097-0142(19950815)76:4<589::aid-cncr2820760408>3.0.co;2-9 CrossRefPubMedGoogle Scholar
- 25.Cancer Statistics in Japan (2018) https://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2017_jp.html. Accessed 30 Aug 2019
- 26.Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T (2017) Familial pancreatic cancer: concept, management and issues. World J Gastroenterol 23:935–948CrossRefGoogle Scholar
- 30.Bang S, Kim HS, Choo YS, Park SW, Chung JB, Song SY (2006) Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas 32:29–36. https://doi.org/10.1097/01.mpa.0000191651.32420.41 CrossRefPubMedGoogle Scholar